NEUTREXIN Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Neutrexin, and what generic alternatives are available?

Neutrexin is a drug marketed by Medimmune Oncology and is included in one NDA.

The generic ingredient in NEUTREXIN is trimetrexate glucuronate. There is one drug master file entry for this compound. Additional details are available on the trimetrexate glucuronate profile page.

Summary for NEUTREXIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	4
Patent Applications:	4,445
Formulation / Manufacturing:	see details
DailyMed Link:	NEUTREXIN at DailyMed

Drug patent expirations by year for NEUTREXIN

Recent Clinical Trials for NEUTREXIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Grupo Oncologico Cooperativo del Sur	Phase 2
U.S. Bioscience	N/A

See all NEUTREXIN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for NEUTREXIN

P01AX	Other agents against amoebiasis and other protozoal diseases
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
P01	ANTIPROTOZOALS
P	Antiparasitic products, insecticides and repellents

US Patents and Regulatory Information for NEUTREXIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-002	Jul 31, 1998		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for NEUTREXIN

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993	⤷ Try a Trial	⤷ Try a Trial
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-002	Jul 31, 1998	⤷ Try a Trial	⤷ Try a Trial
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993	⤷ Try a Trial	⤷ Try a Trial
Medimmune Oncology	NEUTREXIN	trimetrexate glucuronate	INJECTABLE;INJECTION	020326-001	Dec 17, 1993	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for NEUTREXIN

See the table below for patents covering NEUTREXIN around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9959981		⤷ Try a Trial
Luxembourg	88603		⤷ Try a Trial
Australia	4081799		⤷ Try a Trial
Japan	S5799574	2,4-DIAMINO-5-METHYL-6-((3,4,5- TRIMETHOXYANILINO)METHYL)-QUINAZOLINE SALTS	⤷ Try a Trial
Singapore	92087		⤷ Try a Trial
Kenya	3783	WATER-SOLUBLE SALTS OF 2,4-DIAMINO-5-METHYL-6-((3,4,5-TRIMETHOXYANILINO)METHYL)QUINAZOLINE,COMPOSITIONS CONTAINING SUCH SALTS AND THE PRODUCTION OF SUCH SALTS	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for NEUTREXIN

Recent Clinical Trials for NEUTREXIN

Anatomical Therapeutic Chemical (ATC) Classes for NEUTREXIN

Make Better Decisions: Try a trial or see plans & pricing